Literature DB >> 11796764

Protein aggregates and dementia: is there a common toxicity?

S Lovestone1, D M McLoughlin.   

Abstract

This review considers some of the recent advances made in the understanding of the pathogenic proteins known to aggregate and be implicated in neurodegenerative dementing disorders. It concentrates on the two most obvious candidates for the role of toxic protein in Alzheimer's disease (AD)--beta-amyloid peptide and tau--but also considers other proteins in this disorder and in less common but equally devastating diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796764      PMCID: PMC1737746          DOI: 10.1136/jnnp.72.2.152

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  124 in total

1.  hFE65L influences amyloid precursor protein maturation and secretion.

Authors:  S Y Guénette; J Chen; A Ferland; C Haass; A Capell; R E Tanzi
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

2.  Impairment of the ubiquitin-proteasome system by protein aggregation.

Authors:  N F Bence; R M Sampat; R R Kopito
Journal:  Science       Date:  2001-05-25       Impact factor: 47.728

3.  Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease.

Authors:  K S Kosik; C L Joachim; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

Review 4.  Cellular biology of prion diseases.

Authors:  D A Harris
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

5.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Authors:  I Grundke-Iqbal; K Iqbal; Y C Tung; M Quinlan; H M Wisniewski; L I Binder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

7.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Authors:  C Janus; J Pearson; J McLaurin; P M Mathews; Y Jiang; S D Schmidt; M A Chishti; P Horne; D Heslin; J French; H T Mount; R A Nixon; M Mercken; C Bergeron; P E Fraser; P St George-Hyslop; D Westaway
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

Review 8.  Presenilins: molecular switches between proteolysis and signal transduction.

Authors:  W Annaert; B De Strooper
Journal:  Trends Neurosci       Date:  1999-10       Impact factor: 13.837

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome.

Authors:  D M Mann; M M Esiri
Journal:  J Neurol Sci       Date:  1989-02       Impact factor: 3.181

View more
  15 in total

1.  Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption.

Authors:  Emmalee M Jones; Manish Dubey; Phillip J Camp; Briana C Vernon; Jacek Biernat; Eckhard Mandelkow; Jaroslaw Majewski; Eva Y Chi
Journal:  Biochemistry       Date:  2012-03-14       Impact factor: 3.162

Review 2.  Young onset dementia.

Authors:  E L Sampson; J D Warren; M N Rossor
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

Review 3.  Platelet biomarkers in Alzheimer's disease.

Authors:  Leda L Talib; Helena Pg Joaquim; Orestes V Forlenza
Journal:  World J Psychiatry       Date:  2012-12-22

4.  Non-coding RNA as a trigger of neuropathologic disorder phenotypes in transgenic Drosophila.

Authors:  Elena Savvateeva-Popova; Andrej Popov; Abraham Grossman; Ekaterina Nikitina; Anna Medvedeva; Dmitry Molotkov; Nicholas Kamyshev; Konstantin Pyatkov; Olga Zatsepina; Natalya Schostak; Elena Zelentsova; Galina Pavlova; Dmitry Panteleev; Peter Riederer; Michail Evgen'ev
Journal:  J Neural Transm (Vienna)       Date:  2008-09-09       Impact factor: 3.575

Review 5.  Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells.

Authors:  Jorge Ghiso; Silvia Fossati; Agueda Rostagno
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies.

Authors:  Jeremy G Stone; Sandra L Siedlak; Massimo Tabaton; Asao Hirano; Rudy J Castellani; Corrado Santocanale; George Perry; Mark A Smith; Xiongwei Zhu; Hyoung-gon Lee
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

Review 7.  Antioxidant therapy in Alzheimer's disease: theory and practice.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; V Prakash Reddy; Justin C Shenk; Paula I Moreira; Akihiko Nunomura; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

Review 8.  Cerebral amyloidosis: amyloid subunits, mutants and phenotypes.

Authors:  A Rostagno; J L Holton; T Lashley; T Revesz; Jorge Ghiso
Journal:  Cell Mol Life Sci       Date:  2009-11-07       Impact factor: 9.261

9.  Isolation and biochemical characterization of amyloid plaques and paired helical filaments.

Authors:  Agueda Rostagno; Jorge Ghiso
Journal:  Curr Protoc Cell Biol       Date:  2009-09

10.  Age-dependent changes in neuronal distribution of CacyBP/SIP: comparison to tubulin and the tau protein.

Authors:  Anna Filipek; Gabriela Schneider; Anna Mietelska; Izabela Figiel; Grazyna Niewiadomska
Journal:  J Neural Transm (Vienna)       Date:  2008-05-28       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.